#2 - Johnson & Johnson (NYSE:JNJ)
It’s hard to think that a company that has a Covid-19 vaccine candidate would find its stock down for 2020. But as stated in the introduction, the coronavirus is not discriminating when it comes to stocks. Johnson & Johnson (NYSE:JNJ) stock is down over 10%. However, compared to the S&P 500, JNJ has a “less bad” feel to it.
Johnson & Johnson is working with the Biomedical Advanced Research and Development Authority to develop a Covid-19 vaccine. The company expects to begin clinical trials in November. While that doesn’t do much for revenue expectations in 2020, it can be a major catalyst for 2021.
To be fair, JNJ is fighting a couple of different lawsuits which is causing some negative headlines. And despite its size, it is not immune to the residual effects of the coronavirus. For Johnson & Johnson that includes supply chain disruptions and a hard-to-quantify revenue loss as more consumers choose, or are forced to postpone minor or elective health-related procedures and surgeries.
However, Johnson & Johnson came into the current pandemic with a strong balance sheet that included only $18 billion of net debt. The company should not only be able to weather any virus-related headwinds but come out strong on the other side.
The savvy investor knows that you have to answer the door when opportunity knocks, keep reading
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $144.47
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $174.73 (20.9% Upside)
